Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Financial Results

Natco Pharma Financial Results

Natco Pharma approved audited FY26 financial results, reporting consolidated total revenue of ₹4,375.9 Crore. The Board also amended CSR and fair disclosure policies.

Source

BSE filing, NSE: NATCOPHARM. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Natco Pharma Ltd: key numbers

Share price
₹793.00
Market cap
₹15,556 Cr
Revenue (annual)
₹4,078 Cr
Net profit (annual)
₹1,418 Cr
P/E (TTM)
13.6×Sector 46.1×
Promoter holding
49.39%-0.03% QoQ
FII holding
15.99%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Natco Pharma Ltd

All →
14:19 IST NSE
Product Launch

Natco Pharma Product Launch

Natco Pharma launches Carboplatin Injection, a Paraplatin® generic, in the U.S. market via its subsidiary. The oncology product addresses a critical U.S. supply shortage.

17:37 IST BSE
Fund Raise

Natco Pharma Fund Raise of ₹2,000 Cr

Natco Pharma shareholders approved fund raising of up to Rs. 2,000 Crore through various instruments, along with other routine AGM resolutions.

Value
₹2,000 Cr

Other financial results announcements

All →